Table 1.
Baseline Characteristics and Medications at Discharge for 6368 Patients With New‐Onset POAF After Isolated First‐Time Coronary Bypass Surgery and Without OAC
| Variable | Value |
|---|---|
| Male sex | 5170 (81.2) |
| Age, y | 69.9 (7.9) |
| Body mass index, kg/m2 | 27.6 (5.0) |
| Acute coronary syndrome | 3196 (50.2) |
| Heart failure | 825 (13.0) |
| Hypertension | 4727 (74.2) |
| Diabetes | 1915 (30.1) |
| Peripheral vascular disease | 658 (10.3) |
| Previous stroke | 438 (6.9) |
| Previous transitory ischemic attack | 388 (6.1) |
| Arterial embolism | 28 (0.4) |
| Pulmonary embolism | 39 (0.6) |
| Deep vein thrombosis | 129 (2.0) |
| Respiratory disease | 678 (10.6) |
| Renal failure | 233 (3.7) |
| Renal replacement therapy | 26 (0.4) |
| Liver disease | 56 (0.9) |
| History of cancer | 969 (15.2) |
| Antiplatelet therapy | 6181 (97.1) |
| DAPT | 1304 (20.5) |
| Lipid‐lowering agents | 6107 (95.9) |
| β blockers | 5909 (92.8) |
| ACE‐i/ARB | 4888 (76.8) |
| MRA | 750 (11.8) |
| CCB | 1774 (27.9) |
| Diuretics | 3091 (48.5) |
| Digoxin | 135 (2.1) |
| Sotalol | 712 (11.2) |
| Amiodarone | 763 (12.0) |
| Antidiabetics | 1222 (19.2) |
Data are given as number (percentage) or mean (SD). ACE‐i indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; DAPT, dual‐antiplatelet therapy; MRA, mineralocorticoid receptor antagonist; OAC, oral anticoagulation; and POAF, postoperative atrial fibrillation.